This appraisal has been rescheduled following an update from the company. The appraisal is now anticipated to begin in early July 2019 with a submission deadline anticipated late August/early September 2019. This delay means that this appraisal will be removed from the NICE’s reporting targets for timeliness. In addition, through this request for delay the company accepts that this drug will not be eligible to receive interim CDF funding from the date of marketing authorization.